ACHV

Over the past six months, Achieve Life Sciences' stock has significantly increased, rising approximately 183.51% over the past year, 70% over three months, and 31% in the last 30 days as of late August 2026. A key event was the FDA's Complete Response Letter (CRL) in June 2026 for cytisinicline's New Drug Application (NDA), which cited manufacturing issues at a former third-party facility and final product labeling, not efficacy or safety concerns. The market initially sold off but recovered as investors recognized the strong clinical data. In response, the company appointed Adare Pharma Solutions as its new primary manufacturing partner and closed a private placement of up to $354 million, including $180 million upfront, to fund the ORCA-V2 Phase 3 program and commercialization. Achieve Life Sciences plans to resubmit its NDA in Q4 2026, with potential U.S. approval and launch in H1 2027. Recent news also includes new hire inducement equity awards and the launch of a $150 million ATM equity program.